Radiometer Medical India hosted a live webinar on D-dimer

Understanding the concept and value of D-dimers

July 6, 2020

India – July 1, 2020 – Radiometer Medical India, a leading provider of technologically advanced acute care solutions hosted a webinar on D-dimer – Understanding the concept and value yesterday. Garnering an overwhelming participation of critical care specialists, clinicians and laboratory professionals not only from India, but also from other parts of the world, the webinar speaker Guillaume Galpy, underscored the importance of D-dimer in the management of patients with suspected pulmonary embolism (PE) /deep venous thromboembolism (DVT) and how an elevated D-dimer can help in prognosis of COVID-19 patients.

Pulmonary embolism (PE) occurs when a blood clot breaks loose (embolus) and follows the bloodstream to the lungs where it gets stuck and blocks the blood passage causing shortness of breath, coughing, lung-related chest pain¹. Based on several researches and publications released lately, venous thromboembolism (VTE) is known to be frequently reported in COVID-19 cases. Such research works brought out the importance of laboratory testing in such situation. D-dimer is one such biomarker which when used in combination with clinical probability assessment, is used to rule out patients from risk of DVT or PE. Recommendations have been made to prevent and diagnose VTE by including VTE risk assessment scoring for all COVID-19 patients. Further, even if the COVID-19 infection is controlled and stable, whereas the D-dimer levels are rapidly increasing (or if significant increase appear without underlying disease progress) the recommendation is to rule out or confirm DVT by venous echo-Doppler ultrasound of bilateral lower extremities².

Highlighting the meaning of an elevated D-dimer in COVID-19 patients, the webinar focused on research studies and findings that states older age, higher Sequential Organ Failure Assessment (SOFA) score, and elevated D-dimer at admission due to increased coagulation activity, were shown to be risk factors for death of adult patients with COVID-19. The risk factors may help clinicians to identify patients with poor prognosis at an earlier stage.³

The session also accentuated the importance of high quality D-dimer testing, the parameters to define it and the efficiency and cost-effectiveness it brings with it. By using an assay with high specificity, you may rule out 30-50% of all individuals with suspected VTE⁴. High negative predictive value (NPV) allows you to trust the D-dimer results you get by avoiding sending ill patients home⁴. On the other hand, high specificity minimizes imaging on healthy patients benefitting the healthy patient and improving logistics of the healthcare system⁴. Among the various biomarkers of thrombosis, D-dimer is the recommended biomarker as an aid in the diagnosis of VTE (DVT and PE)⁵.

Speaker of the webinar, Guillaume Galpy, has worked on acute care testing for more than 24 years and has been a global industry expert in the field of Immunoassay. He is the name behind the launch of the first Troponin I automated assay in 1995 and several other markers such as natriuretic peptides and D-dimer. After Graduating in Biology and Marketing from the University of Nice and Lyon in France, he joined Radiometer and is currently working as a Global Market Development Manager for Immunoassay at Radiometer Medical, Copenhagen.

To learn more about the webinar and to request access to the recording and slides please visit this page.

[1] Konstantinides S et al. Eur Heart J 2014; 35:3033-69

[2] Zhai Z, Li C, Chen Y, et al. Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. Thromb Haemost. 2020 Apr 21.

[3] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28; 395(10229): 1054-1062.

[4] Strandberg K. The clinical use of a D-dimer assay, Acutecaretesting.org June 2017

[5] Mazzolai L et al.European Heart Journal (2018) 39, 4208–4218 doi:10.1093/eurheartj/ehx003

Cookies are used on this website

Use of cookies

Don't show this message again

Radiometer is using Microsoft AZURE Active Directory to authenticate users

Radiometer uses Azure AD to provide our customers and partners secure access to documents, resources, and other services on our customer portal.

If your organization is already using Azure AD you can use the same credentials to access Radiometer's customer portal.

Key benefits

Allow the use of existing Active Directory credentials
Single-sign on experience
Use same credentials to access future services

Request access

You will receive an invitation to access our services via e-mail when your request has been approved.

When you accept the invitation, and your organization is already using AZURE AD, you can use the same credentials to access Radiometer's customer portal. Otherwise, a one-time password will be sent via e-mail to sign in.

Effective Date January 20th, 2023 (last updated January 20th, 2023)

ABOUT THIS POLICY

Radiometer values your privacy and the protection of your personal data. This policy (“Policy”) explains how Radiometer its affiliates, subsidiaries or related companies, a full list of which can be located here (together, “Radiometer,”, “our”, “us,” or “we”), collects, uses, shares, transfers and processes data collected from or about you.

“Personal Data” is any information that can be used to directly or indirectly identify an individual or that can be reasonably expected to link to an individual. This can include items such as name, address, telephone number, credit card details, email address, ID number, Internet Protocol (“IP”) address of an electronic device used by an individual, or other identifying code (even absent of other identifying information). Statistical and non-identifiable metric data are not considered Personal Data.

The Radiometer subsidiary, affiliate or related company with which you interact is, where applicable, the data controller (or equivalent under applicable law) responsible for the processing of your Personal Data. You can find a list of the relevant legal entities that act as data controllers in Appendix 1 to this Policy.

SCOPE

This Policy describes the types of Personal Data that we may collect, process or disclose about you and how you may govern this processing by exercising applicable legal rights. This Policy applies to both online and offline information collection, including your use of websites or subdomains operated by us, any mobile applications, when we provide products and/or services to you or notify you about prospective items of interest and in other situations where you interact with us in-person, by telephone or by mail where this Policy is posted or referenced.

There may be occasion where you have been provided with a circumstance-specific privacy notice that is separate from this policy, such as privacy notices for specific activities such as Recruitment. To the extent you were provided with a different notice, those notices apply and govern our interactions with you. If you provide Personal Data about parties other than yourself, you are responsible for ensuring their knowledge of how we will process their personal data, and, where applicable, obtaining any necessary consents required in advance.

We are committed to processing Personal Data in accordance with applicable laws. Please note that if you do not wish to provide your Personal Data to us, some products and/or services may become unavailable to you. Your use of any or all these platforms indicates you have been notified of our collection, use, transfer, and disclosure of your information as described in this Policy to the extent permitted by applicable law.